PD L1 News and Research

RSS
Researchers discover mechanism underlying the development and intensification of cancer treatment-related pain

Researchers discover mechanism underlying the development and intensification of cancer treatment-related pain

New therapy-relevant marker may help identify ER+ breast cancer patients who may benefit from immunotherapies

New therapy-relevant marker may help identify ER+ breast cancer patients who may benefit from immunotherapies

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Drug combination elicits efficacious anti-tumor immunity against immunotherapy-resistant cancers

Drug combination elicits efficacious anti-tumor immunity against immunotherapy-resistant cancers

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

Extracellular vesicles enhance cancer immunotherapy

Extracellular vesicles enhance cancer immunotherapy

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

Researchers discover how certain breast cancers persist after chemo and do not respond to immunotherapies

Researchers discover how certain breast cancers persist after chemo and do not respond to immunotherapies

AI could make doctors’ work simpler, faster, and more precise

AI could make doctors’ work simpler, faster, and more precise

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

Immune checkpoint therapy may be beneficial in certain cases of severe COVID-19

Immune checkpoint therapy may be beneficial in certain cases of severe COVID-19

Researchers circumvent a key mechanism in castration-resistant prostate cancer

Researchers circumvent a key mechanism in castration-resistant prostate cancer

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

Study highlights role of tumor-infiltrating B cells, plasma cells in cancer development and treatment outcomes

Study highlights role of tumor-infiltrating B cells, plasma cells in cancer development and treatment outcomes

Research could lead to a new therapeutic option for patients with bladder cancer

Research could lead to a new therapeutic option for patients with bladder cancer

Researchers synthesize a small molecule that can be used to treat a range of cancers

Researchers synthesize a small molecule that can be used to treat a range of cancers

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.